Navigation Links
Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinson's Disease Under Rapid Response Innovation Awards 2008
Date:7/29/2008

ts for the digestive problems that dramatically affect Parkinson's patients' quality of life, as well as test the Braak hypothesis, which posits that Parkinson's disease progresses through the body and to the brain in a series of stages starting in the gastrointestinal system. They are examining a possible link between constipation and Lewy body pathology in the gastric lining of people with PD.

A complete list of 2008 Rapid Response Innovation Awards to date, including researcher bios and grant abstracts, is available at http://www.michaeljfox.org.

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the coming decade through an aggressively funded research agenda. The Foundation has funded $126 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Kevin McHale Instrumental in Forming the Help Me Hear Foundation
11. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Launches Orphan Drug Workshop at KGI 2Daniel K. Spiegelman Elected to Board of Directors of Omeros 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 2Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 3Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 4Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 5Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 6Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 7Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 8Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 9Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 10Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 11Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 12Helix BioPharma Corp. Announces Fiscal Q1 2010 Results 13Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 1Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 2Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 3Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 4Cumberland Pharmaceuticals and Phebra Pty Ltd Sign Exclusive Agreement for Commercialization of Caldolor 28R 29 in Australia and New Zealand 5840 5Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 1Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 2Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 3Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 4Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 5Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 6Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 7Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 8Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 9Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 10Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 11Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 12Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 13Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 14Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 15Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 16Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 17Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 18Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 19Reportlinker Adds Driving Successful Pharma Brands 3A Case Studies of Real Product Launches 5837 20Geneticists hunt for scleroderma triggers 60340 1Geneticists hunt for scleroderma triggers 60340 2